Module leads: Prof Gary Middleton and Prof Mary Keen
Module: code 01 27582
Attendance: Teaching delivered on Mondays for five consecutive weeks
Module dates: 07 Jan 2019, 14 Jan 2019, 21 Jan 2019, 28 Jan 2019, 04 Feb 2019
Learning hours: 150 hours – teaching and private study
Three places on this module are still available for NHS staff, thanks to funding from Health Education England.
Pharmacogenomics is playing a key role in our healthcare system. This module will describe the complexity of pharmacogenomics and the effect of medication on individuals based on their genetic make-up i.e. tailoring drug treatment to improve patient response and techniques to stratify patients at risk of adverse drug reactions. The module will use examples of known validated pharmacogenomic tests relevant to the use of drug treatments.
By the end of the module students should be able to:
- Discuss and evaluate the mechanism of several examples of genomically-determined differential drug response, and drug reaction
- Appraise the strategies and analytical approaches for stratifying patients for optimal drug response or adverse drug reactions including ethnic differences, and how these translate into ‘companion diagnostics’
- Identify and analyse the challenges and limitations of pharmacogenetic studies
- Identify and evaluate the different types of current and emerging biomarkers used in personalised medicine
- Discuss and critically evaluate how genomic information can enable development of drugs targeted for particular genotypes
- Identify the ethical, legal and social issues (ELSI) that could accompany patient stratification for healthcare advice or intervention and defend the use of patient stratification to improve the diagnosis and treatment of disease
Assessment: The module will be assessed via a short presentation, a 3000-word essay assignment and short-answer/case study problems completed in your own time (essay submission date typically around five-six weeks after the teaching).